While broad-spectrum HDAC inhibitors, such as romidepsin and panobinostat, have been shown to exert anti-proliferative effects against osteosarcoma [21], the specific application of Tas and PCI, particularly in combination with doxo, remains largely unexplored. The gene discussed is HDAC9; the disease is osteosarcoma.